Abstract barrestin (barr)-1 and -2 are ubiquitously (outside the retina) expressed G-protein-coupled receptor adapter proteins. They uncouple G-protein-coupled receptors from G proteins, internalize the receptor, and subsequently initiate their own wave of signaling independently of G proteins. Angiotensin (Ang) II type 1 receptor (AT 1 R) is a well-established example of a receptor signaling through barrs. Despite the pivotal role of brain AT 1 Rs in the regulation of blood pressure, the involvement of barr-dependent signaling, mediated by AT 1 Rs is not well studied. Particularly, in brain astrocytes very little is known about the effects of barrs in AT 1 R signaling. Herein, we utilized a combination of pharmacological and gene manipulation approaches to investigate the role of barrs in AT 1 R-mediated signaling in isolated brainstem astrocytes from spontaneously hypertensive rats (SHRs) and Wistar rats. We observed that barr1 is the predominant arrestin isoform at the protein level in these cells. Its expression was down-regulated in SHR astrocytes compared to Wistar rat astrocytes. Ang II, contrary to observations in SHR astrocytes where it had no effect, upregulates barr1 protein in Wistar rat astrocytes. We observed differential involvement of barr1 in MAPK activation in brainstem astrocytes of SHR versus Wistar rats. The barr-biased agonist peptide [Sar 1 , Il 4 , Il8] Ang-II (SII), induced AT 1 Rmediated ERK and p38 activation in Wistar rat astrocytes. SII had no effect on ERK and p38 activation in SHRs brainstem astrocytes. Our results indicate, reduced involvement of barr1 in dampening Ang II-induced MAPKs activation and diminished barr1-mediated ERK and p38 activation in SHR brainstem astrocytes. These findings might be mechanistically related to the development of the brain renin-angiotensinaldosterone system hyperactivity, which leads to pathogenesis of the hypertensive state of the SHR model.
type 1 receptors (AT 1 Rs) and endogenous production of Ang II in the brainstem are the main features of RAAS overactivation (Raizada et al. 1984a,b; Gao et al. 2004) . The spontaneously hypertensive rat (SHR) is a widely employed animal model to study human essential hypertension, and an overactive brain RAAS is one of the most prominent characteristics of SHRs (Amenta et al. 2010) . In these rats, the increase in blood pressure is not apparent until 5-6 weeks of age (Pinto et al. 1998) .
Astrocytes from the cardio-regulatory centers, brainstem and hypothalamus, express the majority of RAAS components and play a pivotal role in the regulation of cardiovascular physiology and blood pressure (Raizada et al. 1987; Tallant et al. 1996; Tallant and Higson 1997; Dampney 2006) . Above all, astrocytes are well-known as a primary source of angiotensinogen peptide, which is the only precursor of Ang II and other RAAS peptides (Lynch et al. 1987; Stornetta et al. 1988 ; Thomas and Sernia 1988; Milsted et al. 1990 ). Astrocytes express AT1Rs, which are functionally different from neuronal AT1Rs (Raizada et al. 1987; Tallant et al. 1996; Tallant and Higson 1997) . Interestingly, there are studies that showed that the astrocytic AT1R expression in the cardio-regulatory center, the brainstem, is higher than the neuronal AT1R in the same brain area (Raizada et al. 1987; Allen et al. 2006; Bourassa et al. 2015) .
Increasing number of in vivo and in vitro studies have demonstrated that astrocytic RAAS is actively involved in the regulation of sympathetic outflow and cardiovascular physiology. Allen et al. (2006) showed that glial-specific over-expression of angiotensinogen (AGT), in the brainstem, in the presence of increased renin activity lead to hypertension. In another study, in renin and AGT transgenic mice, astrocytic-specific ablation of AGT lowered arterial pressure (Sherrod et al. 2005) . Stern et al. (2016) demonstrated that hypothalamic astrocytes, through Ang II and AT1R interaction, function as a key intermediary in Ang II-induced sympathetic outflow and increase in blood pressure. In another study, brainstem astrocytic AT1Rs played a key role in enhancing central sympathetic outflow in heart failure (Isegawa et al. 2014) . Interestingly, the differential modulation of baroreflex by neuron and astrocyte-derived Ang II has been demonstrated. Neuronal derived Ang II caused a selective resetting of the baroreflex to a higher level without changing the sensitivity of the reflex, whereas astrocytic Ang II decreased baroreflex sensitivity (Reid 1992; Sakai et al., 2004) .
barrs are multifunctional regulatory proteins, originally discovered as terminators of agonist-induced G-proteincoupled receptor (GPCR) signaling by a homologous desensitization mechanism . In recent years, it has been appreciated that they also mediate numerous signaling pathways, on their own, leading to regulation of tissue and cellular homeostasis (Shenoy and Lefkowitz 2003; Lefkowitz and Shenoy 2005) . In most cases, barr-dependent signaling are both spatially and temporally distinct from G-protein-dependent signaling. Most importantly, this barr signaling results in unique cellular, physiological, and pathophysiological consequences depending on receptor type, cell/tissue type, and pathophysiological condition (DeWire et al. 2007; Luttrell et al. 2010; Whalen et al. 2011; Lymperopoulos and Negussie 2013) . The AT 1 R is a 7-transmembrane spanning G-protein-coupled receptor (GPCR) (de Gasparo et al. 2000) , which can also initiate barr-dependent signaling, independently of G protein activation (DeWire et al. 2007; Maning et al. 2017) . The AT 1 R mediates most of the angiotensin (Ang) II-induced physiological actions of the RAAS. Previous studies in our laboratory have shown that Ang II activates AT 1 Rs in brainstem and cerebellum primary astrocytes, leading to MAPKs and janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway activation, regulation of inflammation, and astrocyte proliferation (Clark and Gonzalez 2007; Clark et al. 2008 Clark et al. , 2011 Clark et al. , 2012 Delaney et al. 2008; Kandalam and Clark 2010 ). In addition, recent studies have shown that the Ang II-induced AT 1 R-mediated extracellular signal-regulated kinase (ERK1/2) and p38 MAPKs activations are more enhanced in astrocytes derived from brainstems of SHRs as compared to astrocytes derived from normotensive rats (Haspula and Clark 2017) .
The MAPKs play central roles in the regulation of diverse cellular activities such as cellular proliferation and differentiation, gene expression, protein synthesis, and cell survival/ apoptosis (Zhang et al. 2002; Raman et al. 2007 ). Activation of astrocytic MAPKs such ERK, p38 and c-Jun Nterminal kinase regulates cell proliferation, astrogliosis, and mobilization of neuroinflammatory cytokines (driving force for the development of hypertension) (Clark et al. 2001; Gadea et al. 2008; Winklewski et al. 2015) . With regard to barr-dependent signaling, MAPK pathways are the most extensively studied signaling pathways. The existence of barr-dependent signaling involving MAPKs has been demonstrated for various GPCRs in different cell types (Ahn et al. 2004; Gesty-Palmer et al. 2006; Shenoy et al. 2006; DeWire et al. 2007; McLennan et al. 2008) ; however, the majority of the studies have been carried out in heterologous cell models.
barrs are abundantly expressed in brain tissues (Attramadal et al. 1992; Gurevich et al. 2002) . The interactions between barrs and the AT 1 R, and the physiological and pathophysiological implications are well characterized in peripheral cells/tissues such as the kidney, heart, and vasculature (Tohgo et al. 2002; Rajagopal et al. 2006; Kim et al. 2009; Lymperopoulos et al. 2009; Bonde et al. 2010; Maning et al. 2017) . Interestingly, the involvement of brain barrs in AT 1 R-mediated signaling and physiological actions in the brain has not been well studied, not to mention barrs actions in hypertensive conditions. In this study, we employed a biased AT 1 R agonist for barrmediated signaling ([Sar   1   , Il   4 , Il8] Ang-II; SII) (Kendall et al. 2011) , pharmacological inhibition (G protein inhibitor) and gene silencing (barr1 targeting siRNA) approaches to investigate the role of barr1 in Ang II-mediated signaling in hypertensive versus normotensive rat astrocytes derived from the brainstem.
Materials and methods

Materials
The Ang II analog SII (#H-6252), and Ang II (#H-1705) were purchased from Bachem (Torrance, CA, USA). Suramin (#1472), the G protein inhibitor, was purchased from Tocris Bioscience (Minneapolis, MN, USA). The MEK1 inhibitor (PD98059; #9900) was purchased from Cell Signaling Technology (Beverly, MA, USA). The AT1R antagonist, Losartan, was generously donated by Du Pont Merck (Wilmington, DE, USA). The AT2R selective antagonist (PD123319; #P186) was purchased from Sigma (St. Louis, MO, USA). A rabbit polyclonal antibody that recognizes both barrestin 1 and 2 (#sc-28869) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and the beta-actin antibody (#A2066) was purchased from Sigma. The phospho-ERK1/2 (#9101) and Phospho-p38 (#9211) antibodies were purchased from Cell Signaling Technology. For barr1/2 immunostaining, Goat antiRabbit IgG H&L (Alexa Fluor 488 conjugated secondary antibody; #ab150077) was purchased from Abcam (Cambridge, MA, USA). The bicinchoninic acid protein kit (#23225) was obtained from Pierce Biotechnology (Rockford, IL, USA). Quantitative PCR (qPCR) products including the Taqman primer sets for barr1 (Assay ID: Rn01648673_m1), barr2 (Assay ID: Rn01456874_g1), and beta-actin (Assay ID: Rn00667869_m1) were obtained from Applied Biosystems (Foster City, CA, USA).
Predesigned, pool of 4 siRNA molecules targeting rat barr1 gene and non-targeting control siRNA were purchased from Dharmacon (Lafayette, CO, USA). The following siRNA preparations were used: ON-TARGETplus Rat Arrb1siRNA-SMART pool with sequences of GGGUCUGACUUUUCGCAAA; CGACAAAGGG ACACGAGUG, GGAGAACCCAUCAGCGUCA, CGUGAAAUC CUGGGUAUCA and ON-TARGETplus Non-targeting pool with sequences of UGGUUUACAUGUCGACUAA, UGGUUUACAUG UUGUGUGA, GGUUUACAUGUUUUCUGA, UGGUUUACA UGUUUUCCUA, negative siRNA. Transfection reagents, Lipofecamine RNAiMAX (#13778150) and Opti-MEM-Serum reduced media (#31985070) were purchased from Invitrogen (Carlsbad, CA, USA). All other reagents employed in this study were obtained from either VWR international, Fisher Scientific (Waltham, MA, USA) or Sigma.
The following chemicals were used for cell lysate preparation: NaCl (Sigma; Cat. #SX0425-3), sodium fluoride (Sigma; Cat. #215309), EDTA, Triton X-100 (Cat. #423-396), Tris-HCl, sodium orthovanadate (Sigma; Cat. #6508), phenylmethylsulfonyl fluoride (Sigma; Cat. #10837091001), leupeptin (Sigma; Cat. #L2884), and b-mercaptoethanol (VWR, Suwanee, GA, USA; Cat. #80501-154). For the western blot procedure we used the following supplies: nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA, Cat. #1620112), Tween 20 (Sigma; Cat. #P1379), non-fatty milk (Bio-Rad Laboratories; Cat. #170-6404), bovine serum albumin (BSA) (VWR; Cat. #7061-144). For the immunofluorescence assay we employed the following chemicals: paraformaldehyde (VWR; Cat. #AA33314-AP), DAPI (Fisher Scientific; Cat. #D1306), gold anti-fade agent (Fisher Scientific; Cat. #P36930).
Isolation and culture of primary astrocytes Pregnant Wistar rats and SHRs were purchased from Charles River Laboratories (Wilmington, MA, USA) The animals were housed and maintained in the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-accredited animal facility of Nova Southeastern University. All animal protocols were approved by the University Institutional Animal Care and Use committee and complied with the ethical treatment of animals as outlined in the NIH Guide for Animal Care and Use (IACUC approval #: 2017.02.MC1-A1). The brainstem astrocyte cultures were prepared as previously described (Tallant and Higson 1997) . The whole brains from 2-to 3-day-old rat pups were isolated and the brainstems were dissected from each brain. Astrocyte cultures were then prepared from the pooled brainstems by physical dissociation. The cells were grown in Dulbecco's modified Eagle medium/nutrient mixture F-12 (VWR, Cat. #45000-350) culture media containing 10% fetal bovine serum (VWR, Cat. #89510-186), 10 000 IU/mL penicillin, 10 000 lg/mL streptomycin, and 25 lg/ mL amphotericin B (VWR, Cat. #45000-616) at 37°C in a humidified incubator (5% CO2 and 95% air). The cell cultures were fed every 3-4 days. On attaining confluency, the cells were shaken for 24 h in order to detach microglia and oligodendrocytes. Afterward, the cells were detached with trypsin/EDTA (0.05% trypsin, 0.53 mM EDTA) (VWR, Cat. #45000-660) and replated at a ratio of 1: 10. The astrocyte enriched cultures were fed once every 3 days until they were about 90% confluent. Before all cell treatments, astrocytes were made quiescent by treating with serumfree media for 48 h. All treatments were accomplished in serum-free dulbecco's modified Eagle medium/nutrient mixture F-12 culture media containing 10 000 IU/mL penicillin, 10 000 lg /mL streptomycin, and 25 lg /mL amphotericin B. The purity of the astrocyte cultures was assessed using qPCR, western blotting, and flow cytometry as described (Haspula and Clark 2016) . Each independent experiment was done on brainstem primary astrocytes cultured from one litter of pups pooled from a single Wistar rat or SHR. Each n represents brainstem astrocytes pooled from one litter of pups obtained from one independent animal, SHR or Wistar rat.
Small interfering RNA (siRNA) transfection
We have successfully knocked down barr1 expression using the SMARTpool siRNAs from Dharmacon RNAi Technologies. Cells grown to~70-80% confluence in six well plates were transfected with 80 nM barr1 siRNA using 20 lL Lipofectamine RNIMAX (Invitrogen) in Opti-MEM. Astrocytes were also transfected with control or scrambled siRNA from Dharmacon in a similar fashion. After 48 h transfection (for mRNA estimation) and 96 h transfection (for protein estimation and post-transfection treatments), the cells were serum starved (media with 0.1% serum) for at least 48 h prior to stimulation.
Cell treatments
Serum starved astrocytes were treated with 100 nM Ang II or 10 lM SII for varying time periods. In the MAPK experiments, cells were treated with 100 nM Ang II for 10 min as previous studies have shown a maximal response of the peptide to induce these intracellular signals under these conditions (Haspula and Clark 2017) . To assess time-dependent Ang II effects on barr1 protein, the cells were treated for time periods of 4, 6, 8, 12, 16, 24 , and 48 h. For barr1 mRNA estimation, the time periods were 4, 8, 12, 16, and 24 h. For P-ERK1/2 estimation, the time period of Ang II or SII treatments was 10 min. For the inhibitor studies, the cells were pretreated with 10 lM Losartan (AT1R inhibitor), 10 lM PD123319 (AT2R inhibitor), 100 lM Suramin (G protein inhibitor), or 10 lM PD98059 (MEK1 inhibitor) for 30 min before Ang II or SII treatments for varying times. The times for Ang II treatments for the inhibitor studies were selected based on the earliest common point, where the difference observed with respect to its control, was statistically significant. For all experiments, cells that received no treatments were used as the control.
Cell lysate preparation
Following treatments, cell lysates were prepared by washing cells with phosphate-buffered saline (PBS), followed by the addition of supplemented lysis buffer (100 mM NaCl, 50 mM sodium fluoride, 5 mM EDTA, 1% Triton X-100, 50 mM Tris-HCl, 0.01 mM sodium orthovanadate, 0.1 mM phenylmethylsulfonyl fluoride, and 0.6 lM leupeptin, pH 7.4). Protein concentrations were determined using the bicinchoninic acid assay as per the manufacturer's instructions. After protein determinations, bmercaptoethanol (5%) and bromophenol blue (0.01%) were added to the samples, and the cell lysates were stored at À80°C until further processing.
Total RNA extraction and mRNA expression We employed the trizol method to extract total RNA from our astrocytes culture. Briefly, trizol reagent (1 mL) was used to collect the cell lysate from 100 mm culture plates. For RNA isolation, 1-Bromo3-chloroPropane (200 lL/1 mL trizol) was added to the cell lysate. This was followed by a mixing and centrifugation procedure, which resulted in two phases; the upper aqueous RNA containing phase was transferred to a new tube. Cold isopropanol (500 lL) was added to the aqueous solution which was followed by a mixing and centrifugation step which resulted in a jelly-like pellet. The jelly-like pellet was resuspended in 75% ethanol and briefly vortexed and centrifuged. The supernatant was discarded and the RNA pellet air dried. Finally, the RNA pellet was resuspended in RNase-free water. The RNA concentration and purity were determined using a BioRad SmartSpec Plus Spectrophotometer (Bio-Rad Laboratories). A ratio value of A260/A280 close to 2 was considered as an indicator of good purity of our RNA samples. Reverse transcription from total RNA (2 lg) to complementary strand DNA was done using a high capacity reverse transcription reagent kit (Applied Biosystems; Cat. #4368813). qPCR was performed using the TaqMan Universal master mix (Cat. #4304437), and the TaqMan gene expression primers (Applied Biosystems) for the barr1 gene (ARRB1) or barr2 gene (ARRB2). Samples were analyzed in 96-well plates using the StepOne TM plus Real time PCR system from Applied Biosystems (Cat. #4376600). The mRNA data are normalized to the levels of the housekeeping control gene (beta-actin) and expressed as fold change in the expression of the gene of interest (barr1 or barr2) in treated/ untreated cells, as compared with the reference gene (barr1 or barr2) in untreated cells.
Western blotting 15 to 35 lg of solubilized proteins were loaded into 10% polyacrylamide gels (Bio-Rad Laboratories; Cat. #4561003), and subsequently transferred to nitrocellulose membranes. The membranes were subsequently blocked with 5% non-fatty dry milk prepared in tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T). The membranes were then subjected to three washes, 5 min, each using TBS-T followed by incubation with an anti-barr1/2 (1 : 350), P-ERK1/2 (1 : 5000) or P-p38 (1 : 10 000) polyclonal antibody, prepared in TBS-T containing 5% non-fatty milk or 5% BSA, at 4°C overnight. The membranes were then subsequently washed and probed with an anti-rabbit secondary antibody for 1 h at 25°C. After another round of washes, the immunoreactive bands were visualized using enhanced chemiluminescence reagent (Pierce Biotechnology, Waltham, MA, USA, Cat. #34095) by western blot imaging machine-Fluorchem E (Cell Bioscience, Santa Clara, CA, USA; Model #FE0232) and quantified by densitometric analysis using the Image J software (National Institute of Health (NIH), Bethesda, MD, USA). The membranes were then stripped and reprobed with a betaactin antibody at a concentration of 1 : 5000. The barr1, P-ERK1/2, or P-p38 bands were then normalized to beta-actin.
Immunofluorescence
Astrocytes were grown on coverslips to 40-50% confluency. The cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.2% Triton X-100 for 10 min, and blocked with 1% BSA for 1 h. The cells were incubated with the barr1/2 primary antibody (Santa Cruz Biotech) for 1 h at 25°C, followed by incubation with the Alexa Fluor 488 (green) conjugated secondary antibody (Abcam) for 1 h. This step was followed by three washes with PBS and the cover slips were incubated with 300 nM DAPI for 1-3 min, which was followed by three to four washes with PBS. Mounting medium containing gold anti-fade agent was added on the cover slips. The staining for barr1/2 was visualized by fluorescence microscopy (Olympus, Center-Valley, PA, USA; Model #IX51S8F-2).
Statistical analysis
All data are generally expressed as the mean AE SEM for three or more experiments. A 2 9 2 mixed ANOVA was employed to determine if there were any significant differences in the basal values between SHRs and Wistar rats. A two-way ANOVA was employed for testing the effect of Ang II on barr1/2 in SHRs as compared to Wistar rats. A t-test followed by Bonferroni post hoc test was employed to determine significant differences between treatments and the respective control in different strains. In order to make comparisons between identical time points from different rat models, a Student's t-test was employed. In this study no blinding experiments were performed. In addition, no assessment of outliers and normality of the data were done.
Results
Cellular localization and expression levels of barrestin1 and 2 The qPCR assay revealed that barr1 mRNA levels are significantly higher than barr2 mRNA levels in both SHR and Wistar rat brainstem astrocytes ( Fig. 1a and b) .
Comparing the mRNA expression levels of barr1 and 2 in SHR and Wistar rat brainstem astrocytes showed that the barr1 mRNA level is significantly higher in Wistar rat astrocytes as compared to SHR astrocytes (Fig. 1c) . On the other hand, we observed no significant differences in barr2 mRNA expression in both SHR and Wistar rat astrocytes (Fig. 1d) . In the western blot and immune-staining experiments, we employed an antibody that recognizes both barr1 and 2 proteins. The immunostaining assay showed that the majority of barrestin protein was localized in the nucleus in both models ( Fig. 2a and b) . In almost all our western blots, we observed only a single protein band which corresponds to barr1 protein. As shown in Fig. 2c , the barr2 protein level is very low and almost negligible in our cell model. Further, the barr1 protein level is significantly higher in normotensive Wistar rat astrocytes as compared to SHR astrocytes (Fig 2d) .
Taken together, the qPCR, the western blot, and immunostaining data showed that barr1 is the dominant arrestin in astrocytes derived from brainstems of SHRs and Wistar rats and its expression levels are significantly lower in brainstem astrocytes isolated from SHRs as compared to normotensive Wistar rats.
Effect of Ang II on barrestin1 levels in Wistar and SHRs brainstem astrocytes Very little is known about the cellular factors involved in the regulation of barr1 and 2 expressions. In order to determine if Ang II has any effect on barr1 expressions in astrocytes isolated from the brainstems of SHRs and Wistar rats, we treated quiescent astrocytes with 100 nM Ang II for different time periods (1-48 h). This concentration was optimal for activation of astrocytic AT 1 Rs as previously reported by our laboratory (Clark and Gonzalez 2007) . Ang II, contrary to SHR astrocytes where it has no effect, up-regulates barr1 protein expression in astrocytes from Wistar rats (Fig. 3a) . This effect was significant at the majority of the time points examined. The maximum effect was observed after 24 h of treatment. Regarding the Ang II effect on barr1 mRNA expression, in both SHRs and Wistar rats' brainstem astrocytes, the overall effect was down-regulation (Fig 3b) . Despite negligible levels of AT 2 R expression in our astrocyte culture (data not shown), we employed inhibitor studies to specify the receptor mediating Ang II effects. As Ang II-induced barr1 protein synthesis was not observed in SHR brainstem astrocytes, inhibitor studies were only conducted in Wistar brainstem astrocytes. Wistar brainstem astrocytes were treated with 100 nM Ang II for 4 h, in the presence and absence of the inhibitors. As shown in Table 1 , pre-treating the cells with either the AT 1 R inhibitor (Losartan) or the AT 2 R inhibitor (PD123319) alone had no significant effect on Ang II-induced barr1 protein expression levels. However, Losartan prevented Ang II's effects on the barr1 protein levels in Wistar rat brainstem astrocytes. PD123319 was ineffective in preventing Ang II's effects on these cells.
Effect of Ang II and SII on MAPKs activation in Wistar and SHRs brainstem astrocytes
One of the main focus of our study was to investigate the involvement of barr1 in the AT 1 R-mediated MAPK activation in our astrocyte cultures using SII (a partial biased AT 1 R agonist which selectively activates barrestin-dependent signaling). We compared the SII effect with the Ang II effect (the non-biased and full AT 1 R agonist). In order to investigate this, quiescent confluent astrocytes derived from brainstems of SHRs and Wistar rats were treated with either 10 lM SII or 100 nM Ang II for 10 min. These SII and Ang II concentrations are optimal for AT 1 R-mediated ERK1/2 activation in different cell systems (Clark and Gonzalez 2007; Kim et al. 2009; Lymperopoulos et al. 2009 ). We employed western blotting technique and probed with antibodies that detected P-ERK1/2 and P-p38 MAPK.
As expected, Ang II-induced ERK1/2 and P38 MAPK activation in both Wistar and SHRs astrocytes. This effect was significantly higher, almost by 2-fold, in SHR brainstem astrocytes as compared to Wistar rat brainstem astrocytes ( Fig. 4a and c) . On the other hand, SII-induced ERK1/2 and P38 MAPKs activation in Wistar rat brainstem astrocytes, by Represents barr1/2 immunostaining in Wistar rat astrocytes; (b) represents barr1/2 immunostaining in SHR astrocytes. The immunostaining was done using a primary antibody that recognizes both barr1and 2, as described; (c) barrestin1 and 2 basal protein expression in primary astrocytes derived from brainstems of Wistar rats. Protein sample was collected from untreated astrocytes isolated from the brainstem of the Wistar rat model and western blotting procedure was done as described. The blots were probed with a primary antibody which recognizes both barr1 and 2; (d) comparison of basal protein levels of barr1 in SHRs versus Wistar rats brainstem astrocytes. Cell lysates prepared from untreated astrocytes derived from brainstem of SHRs and Wistar rats, were analyzed for barr1/2 levels using the western blotting technique as described. The blots were probed with a primary antibody which recognizes both barr1 and 2. The data were analyzed using densitometry and barr1/2 levels were normalized to a loading control, beta-actin. Each box represents the values of preparations of brainstem astrocytes from three independent litters of neonatal rat pups. Black line within the boxes marks the median; symbol X within the boxes marks the mean; the whiskers above and below the boxes indicate the maximum and minimum values of the data. more than 2-fold, but surprisingly SII did not induce these MAPKs in SHR brainstem astrocytes ( Fig. 4b and d) . The SII-induced ERK1/2 activation, in Wistar rats, was inhibited by the MEK1 inhibitor (PD98059) ( Table 2) .
Effect of suramin on Ang II-and SII-induced ERK1/2 activation In the previous section, we observed that SII induced ERK1/ 2 and p38 MAPKs activation in astrocytes derived from brainstems of Wistar rats. This effect was not observed in astrocytes derived from brainstems of SHRs. On the other hand, Ang II induced ERK1/2 and p38 MAPK activation in astrocytes derived from brainstems of both Wistar and SHRs. Furthermore, the Ang II effect was significantly higher in SHR astrocytes as compared to Wistar rat astrocytes. To delineate the role of G protein-dependent and barr-dependent signaling in the Ang II-induced ERK1/2 activation, we employed Suramin to inhibit the G-protein-dependent signaling. Suramin is a pharmacological inhibitor used to inhibit GPCR-mediated G protein activation by interrupting the GTPase cycle. By this action, it blocks G-protein-dependent signaling (Beindl et al. 1996; Chung and Kermode 2005; Morinelli et al. 2009; Michel and Seifert 2015) . Based on our investigation, and previous reports done by others (Chung and Kermode 2005) , 100 lM Suramin was the optimal concentration for inhibition of AT 1 R-mediated G protein activation. Quiescent confluent astrocytes from SHRs and Wistar rats were pre-treated with 100 lM Suramin for 30 min followed by treatment with 100 nM Ang II for 10 min. In addition, we investigated whether Suramin has Fig. 3 Time-dependent Ang II effects on barr1 mRNA expression and protein expression levels in SHRs and Wistar rats brainstem astrocytes. Quantitative polymerase chain reaction (qPCR) was employed to compare barr1 mRNA levels from SHRs and Wistar rat brainstem astrocytes, which were pre-treated with 100 nM Ang II for varying time periods. The data are presented as fold of control that were obtained when barr1or 2 C T values were normalized to betaactin C T values and further normalized to its control. Western blotting was employed to compare barr1 protein levels from SHRs and Wistar rats brainstem astrocytes, which were pre-treated with 100 nM Ang II for varying times. The data are presented as fold of control that were obtained when barr1 levels were normalized to beta-actin; these values were further normalized to its control. (a) Depicts time-dependent Ang II effect on barr1 protein expression levels in SHRs and Wistar rats brainstem astrocytes. Each box represents the preparations of brainstem astrocytes isolated from five litters of neonatal rat pups; (b) depicts Ang II effects on barr1 mRNA levels in SHRs and Wistar rats brainstem astrocytes at different time points. Each box represents the values of preparations of brainstem astrocytes isolated from six independent litters of neonatal rat pups. Black line within the boxes marks the median; symbol X within the boxes marks the mean; whiskers above and below the boxes indicate the maximum and minimum values of the data. effects on SII-induced ERK1/2 activation in Wistar rat astrocytes by employing a similar protocol by treating with 10 lM SII for 10 min. The western blot data showed that Suramin significantly inhibited Ang II-induced ERK1/2 MAPK activation in both SHR and Wistar rat brainstem astrocytes; however, this Ang II effect was not completely abolished ( Fig. 5a and b) . In Wistar rat astrocytes (Fig. 5a) , Suramin reduced the Ang IIinduced ERK1/2 activation by close to 2-fold, almost to the level of SII-induced ERK1/2 activation. On the other hand, in SHR astrocytes (Fig. 5b) , Suramin suppressed Ang IIinduced ERK1/2 activation by almost 4-fold, which is more Fig. 4 Comparison of SII and Ang II effects on ERK1/2 and p38 MAPK activation in SHRs and Wistar rats brainstem astrocytes. Quiescent brainstem astrocytes were pre-treated with 10 lM SII or 100 nM Ang II for 10 min. The cell lysates were subject to western blotting analysis and probed with a P-ERK1/2 or a P-p38 antibodies. The data are presented as fold of control that were obtained when P-ERK1/2 and P-p38 bands were normalized to beta-actin and further normalized to their controls. (a) Depicts Ang II effect on ERK1/2 activation in SHRs and Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from five litters of neonatal rat pups; (b) depicts SII effect on ERK1/2 activation in SHR and Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from five litters of neonatal rat pups; (c) depicts Ang II effect on p38 activation in SHR and Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from three litters of neonatal rat pups; (d) depicts SII effect on p38 MAPK activation in SHRs and Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from three independent litters of neonatal rat pups. Black line within the boxes marks the median; symbol X within the boxes marks the mean; whiskers above and below the boxes indicate the maximum and minimum values of the data.
robust than its effect in Wistar astrocytes. These Suramin effects on Ang II-induced ERK1/2 activation were not observed in the SII-induced ERK1/2 activation (Fig. 5c ), which validates that Suramin inhibition effect is selective to G-protein-dependent ERK1/2 MAPK activation.
Effect of barr1 knock down on Ang II-and SII-induced ERK1/2 activation
To further validate the G-protein-independent signaling in AT 1 R-mediated MAPKs activation in our astrocyte cultures, we examined the effects of siRNA-mediated suppression of barr1 on ERK1/2 activation following stimulation with Ang II and SII. siRNAs transfection was done according to the manufacturers protocol as described in the methods section. Transfection with siRNAs targeting barr1, significantly silenced the mRNA and protein expression of barr1 in astrocytes derived from brainstems of SHR and Wistar rats. We achieved close to 90% suppression in mRNA levels of barr1 (Fig. 6a ) and 60% suppression in protein expression levels of barr1 in both models (Fig. 6b and c) .
Assessing the transfection effect in the SII-induced ERK1/2 activation revealed that in barr1 siRNA transfected Wistar rat brainstem astrocytes, SII-induced ERK1/2 activation was completely abolished as compared with the SII effects in control siRNA (-ve siRNA) transfected and non-transfected astrocytes (Fig. 7a) . As shown previously in Fig. 4b , SII marginally activates ERK1/2 in SHR brainstem astrocytes. No barr1 knockdown effect was observed on SII's ERK1/2 effect in SHR brainstem astrocytes (data not shown).
In barr1 siRNA transfected Wistar rat brainstem astrocytes, Ang II-induced ERK1/2 activation was significantly decreased by more than 50% as compared with the Ang II effects in control siRNA (-ve siRNA) transfected and nontransfected astrocytes (Fig. 7b) . In astrocytes derived from the brainstems of SHRs, barr1 siRNA transfection reduced Ang II-mediated ERK1/2 activation by almost 20% as compared with the Ang II effects in control siRNA (-ve siRNA) transfected and non-transfected astrocytes (Fig. 7c ).
This suppression effect was lower as compared to the suppression effect observed in Wistar rats.
As demonstrated before, barr2 expression in our cell model is negligible and its protein was undetectable, suggesting that barr1 is the major arrestin in our cells. To confirm this, we employed siRNA targeting barr2 in our cell model to assess whether it has any effect on SII and Ang IIinduced ERK1/2 activation. We observed no significant effect on either SII-or Ang II-induced ERK1/2 activation in both SHRs and Wistar rats' brainstem astrocytes (data not shown). This demonstrates that barr2, most likely, does not play a role in barr-dependent MAPKs activation in our cell model.
Effect of Suramin on Ang II-Induced ERK1/2 activation in barr1 knock down Wistar and SHRs brainstem astrocytes
To further expand our understanding of AT 1 R-mediated ERK1/2 activation in our cell model, we employed a combination of pharmacological inhibition and gene silencing treatments. Within this framework, we assessed Suramin effect on Ang II-induced ERK1/2 activation in posttransfected astrocytes derived from brainstems of SHRs and Wistar rats.
As shown in Fig. 8a , in barr1 siRNA transfected Wistar rat brainstem astrocytes, Suramin significantly reduced Ang IImediated ERK1/2 activation, almost to the basal level, as compared to the Ang II effects in control siRNA (-ve siRNA) transfected and non-transfected brainstem Wistar rat astrocytes. In barr1 siRNA transfected SHRs brainstem astrocytes, Suramin totally abolished Ang II-mediated ERK1/2 activation (Fig. 8b) as compared to the Ang II effects in control siRNA (-ve siRNA) transfected and non-transfected SHR brainstem astrocytes. This effect was not observed in barr2 siRNA transfected SHR brainstem astrocytes (data not shown).
Although not significant, there is a difference in Suramin effect on Ang II-induced ERK1/2 activation in barr1 siRNA post-transfected SHR astrocytes as compared to posttransfected Wistar rat astrocytes. In barr1 siRNA posttransfected Wistar rat astrocytes, Ang II-induced ERK1/2 activation was not completely abolished. Perhaps, the reason for this could be inadequate depletion of barr1 in Wistar rat astrocyte.
Discussion
In this study, we report, for the first time to our knowledge, that barr1 is the major arrestin isoform in rat brainstem primary astrocytes. Additionally, barr1 levels are lower in SHR brainstem astrocytes than in Wistar brainstem astrocytes. Importantly, Ang II, up-regulates barr1 in Wistar rat brainstem astrocytes, while it has no effect in SHR. Finally, barr1 mediates less AT 1 R-induced ERK activation in astrocytes derived from brainstems of SHRs, compared to astrocytes derived from the brainstems of Wistar rats. The fact that barr1 is the predominant isoform in rat astrocytes is consistent with the vast majority of the literature reporting a much higher protein abundance (~10-15-fold) of barr1 over barr2 in almost every tissue/organ of almost every mammalian species, including humans, mice, and rats (Zhan et al. 2011; McCrink et al. 2017a,b) . It has been reported that in normal physiological conditions, barr1 and 2 are differentially expressed in rat brain regions (Attramadal et al. 1992; Gurevich et al. 2002) . In the majority of brain regions, barr1's mRNA and protein expression levels are more Fig. 5 Effect of Suramin on Ang II and SII-induced activation of ERK1/2 in SHRs and Wistar rats' brainstem astrocytes. Quiescent brainstem astrocytes were pre-treated with 100 lM Suramin for 30 min followed by treatment with 100 nM Ang II or 10 lM SII for 10 min. Other samples were treated with Ang II (100 nM) alone, 10 lM SII alone, or Suramin (100 lM) alone for 10 min. The cell lysates were subjected to western blotting analysis and probed with a P-ERK1/2 antibody. The data are represented as fold of control that were obtained when P-ERK1/2 bands were normalized to beta-actin bands and further normalized to its control. (a) Depicts Suramin effect on Ang II-induced activation of ERK1/2 in Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from five litters of neonatal rat pups; (b) depicts Suramin effect on Ang II-induced activation of ERK1/2 in SHRs brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from five litters of neonatal rat pups; (c) depicts Suramin effect on SIIinduced activation of ERK1/2 in SHRs and Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from three independent litters of neonatal rat pups. (Sur = Suramin). Black line within the boxes marks the median; symbol X within the boxes marks the mean; whiskers above and below the boxes indicate the maximum and minimum values of the data.
dominant as compared to barr2. Particularly, extensive expression of barr1 is observed in rat brainstem tissue (Attramadal et al. 1992) . Furthermore, barr1 and 2 have different intracellular localizations. Contrary to barr2, under basal conditions, barr1 is able to localize in the nucleus (Scott et al. 2002; Wang et al. 2003) . It has been observed that barr1 and 2 physiological levels are altered in various human diseases, including Parkinson's disease, multiple sclerosis, type 2 diabetes, coronary artery disease, inflammatory diseases, and various cancers (Whalen et al. 2011) .
Regarding barr1 and 2 expression in hypertension, two contradictory research findings are reported. The first is a recently reported research work done in pre-sympathetic neurons from the rostral ventrolateral medulla of SHRs (Sun et al. 2018) . In this study, it was demonstrated that barr1 protein expression levels was significantly down-regulated in SHRs compared to normotensive Wistar Kyoto (WKY) rats. Moreover, this study indicated that barr1 expression is significantly lower in the late stage of hypertension compared to the pre-hypertension stage. The second reported finding is an investigation done in mesenteric arterial smooth muscle cells isolated from 6-and 12-week-old SHRs (Willets et al. 2015) . In this study, it was demonstrated that both barr1 and 2 expression were increased in mesenteric arterial smooth muscle cells of 12-week-old SHR (with the onset of hypertension) compared with age matched normotensive WKY controls, whereas no differences were observed between 6-week-old SHRs (pre-hypertensive condition) and age matched WKY rats.
In our study, we measured the expression of barr1 and 2 in unstimulated brainstem astrocytes. From both mRNA and protein data, we observed that barr1 is the major endogenously expressed arrestin protein isoform in our cell model. Our results correlate well with findings reported by others (Gurevich et al. 2002) . Similar expression pattern of barr1 was observed in adrenocortical zona glomerulosa cells (Lymperopoulos et al. 2009 ). Our immunostaining results showed that the majority of arrestin protein in astrocytes from the brainstems of SHRs and Wistar rats was localized in the nucleus. As the barr1 isoform is the form that can localize in the nucleus (Scott et al. 2002; Wang et al. 2003) , this further supports our conclusion that barr1 is the dominant arrestin in SHR and Wistar rat brainstem astrocytes.
One interesting finding we have from this study is the differential expression of barr1 in SHR brainstem astrocytes, compared to normotensive Wistar rat astrocytes. The mRNA data showed that barr1 mRNA expression is significantly higher in Wistar rat astrocytes as compared to SHR astrocytes. Similar to the mRNA expression, barr1 protein levels were significantly higher in astrocytes from Wistar rats as compared to astrocytes from SHRs. Our result strongly agrees with the finding reported by Sun et al. (2018) , while it negates the results reported by Willets et al. (2015) . The fact that we are dealing with totally different organs, tissues and cellular systems could be enough reasons for this difference. Our findings combined with others' (Willets et al. 2015; Sun et al. 2018) , support the concept that the alteration in barr1 and 2 expression levels and their roles are organ, tissue, cell, and phenotype specific.
Interestingly, the overall Ang II effects on barr1 mRNA levels were similar in both SHRs and Wistar rat's brainstem astrocytes, which revealed down-regulation at all-time points examined. Possibly, the Ang II effect on barr1 levels is on the post-transcriptional cellular activities. These actions could include enhancing translational efficiency, increasing post-translational modifications, increasing protein stability and/or short mRNA turn over as a result of Ang II-mediated decrease mRNA stability (Maier et al. 2009 ). Based on the inhibitor data and the fact that we observed negligible AT 2 R expression levels in our SHRs and Wistar rats' brainstem astrocytes (data not shown), this Ang II effect is most likely mediated through AT 1 Rs. This is again consistent with the notion that the other Ang II receptor type, AT 2 R, although present in most tissues and cell types including brain-derived astrocytes, is incapable of signaling through either G proteins or barrs and exerting any physiological effects (Zhang et al. 2017) . In other words, it merely acts as a 'decoy' Ang II receptor in vivo, hence the fact it counteracts most (if not all) of Ang II actions mediated by the AT 1 R.
Ang II via brainstem AT 1 Rs has been demonstrated to have a pressor effect that is significantly more dominant in SHRs when compared to Wistar rats (Seyedabadi et al. 2001) . In addition, the brainstem astrocytic AT1R has been shown to play an important role in augmenting sympathetic outflow (Isegawa et al. 2014) . A possible theory that could be formulated from these differential effect of Ang II on barr1 protein levels is that an elevation in barr1, in response to AT 1 R activation, in normotensive Wistar rats may be a homeostatic mechanism to counteract the detrimental nature of the Ang II-induced AT 1 R-mediated signaling under hypertensive conditions. This protective mechanism possibly is disrupted in SHR brainstem astrocytes. This assumption is supported by the recently reported in vivo study which demonstrated that over-expression of barr1 in SHR rostral ventrolateral medulla using a barr1 gene delivery technique reduced blood pressure and sympathetic outflow (Sun et al. 2018) . The proposed mechanism for this barr1 effect is through nuclear factor kappa B (NF-kB)-mediated AT 1 R down-regulation. Even though our finding is the first to show Ang II-induced AT 1 R-mediated barr1 regulation in Wistar rats brainstem astrocytes, Oakley et al. (2012) have shown that glucocorticoid-induced protease-activated receptor 1-mediated barr1 up-regulation in vascular smooth muscle cells (VSMCs) shifted the signaling course of the receptor from Gprotein-dependent to barr1-dependent.
Our current findings lead us to suggest that the impairment of regulatory systems in SHR brainstem astrocytes could be one of the molecular features that may lead to hypertension. The impairment of Ang II-induced barr1 regulation shows the absence of the cellular mechanism which maintains the physiological levels of barr1 cellular pools crucial for the regulation of AT 1 R-mediated signaling in SHR brainstem astrocytes. It is plausible that this impaired condition is among the driving forces that lead to over activation of the RAAS leading to hypertension. Another significant finding from our study is the diminished involvement of barr1 in AT 1 R-mediated MAPKs activation in astrocytes derived from brainstems of SHRs as compared to astrocytes derived from the brainstems of Wistar rats. We observed that Ang II-induced AT 1 R-mediated ERK1/2 activation in Wistar rat brainstem astrocytes is mainly G-protein and barr1-dependent. While in SHR brainstem astrocytes, it seems almost exclusively G protein dependent. Fig. 6 Effect of barr1 targeting siRNA on barr1 mRNA expression and protein levels in SHRs and Wistar rats brainstem astrocytes. Astrocytes were transfected with transfection reagent (RNAiMAX) alone, non-silencing siRNA (-ve-siRNA), or barr1 targeting siRNA as described in the methods part. (a) Depicts barr1 mRNA expression levels after siRNA transfection. Quantitative polymerase chain reaction (qPCR) was employed to assess barr1 mRNA levels. The data are presented as fold of control that were obtained when barr1 C T values were normalized to beta-actin C T values and further normalized to its control. Each box represents the values of preparations of brainstem astrocytes isolated from three litters of neonatal rat pups; (b) depicts barr1 protein levels in Wistar rat astrocytes after siRNA transfection. Each box represents the values of preparations of brainstem astrocytes isolated from four litters of neonatal rat pups; (c) depicts barr1 protein levels in SHR astrocytes after siRNA transfection. Protein levels were analyzed using western blotting technique as described. Each box represents the values of preparations of brainstem astrocytes isolated from three independent litters of neonatal rat pups. The blots were probed with a primary antibody which recognizes both barr1 and 2. The data were analyzed using densitometry and barr1 bands were normalized to a loading control, beta-actin and further normalized to their control. Black line within the boxes marks the median; symbol X within the boxes marks the mean, whiskers above and below the boxes indicate the maximum and minimum values of the data.
Roles of barrs as signal transducers have been extensively studied and well characterized for SII-induced AT 1 Rmediated MAPKs activation in several heterologous cell models and peripheral cells/tissues (Ahn et al. 2004; Kim et al. 2009; Lymperopoulos et al. 2009; Oakley et al., 2009) . In this study, for the first time, we have shown SIIinduced AT 1 R-mediated MAPKs (ERK1/2 and p38) activations in astrocytes derived from brainstems of Wistar rats. The SII-induced ERK1/2 activation was sensitive to the MEK1 inhibitor (PD98059). Surprisingly, SII-induced MAPKs activation was marginal in astrocytes derived from brainstems of SHRs compared to its effect in Wistar brainstem astrocytes. On the other hand, Ang II induced AT 1 R-mediated MAPKs phosphorylation in astrocytes isolated from brainstems of SHRs and Wistar rats. Interestingly, this Ang II effect was significantly higher in brainstem astrocytes from the SHRs as compared to astrocytes from the Wistar rats. The same effect was observed in SHR brainstem astrocytes and SHR VSMCs by others (Wilkie et al. 1997; Haspula and Clark 2017 ). It appears that the impairment of Fig. 7 Effect of barr1 targeting siRNAs on Ang II and SII-induced ERK1/2 activation in SHR and Wistar rats' brainstem astrocytes. Posttransfected or non-transfected serum starved astrocytes were treated with 100 nM Ang II or 10 lM SII for 10 min, as described. Cell lysates were subjected to western blotting analysis and probed with a P-ERK1/ 2 antibody. The data are presented as fold of control that were obtained when P-ERK1/2 bands were normalized to beta-actin and further normalized to their control. (a) Depicts effect of barr1 targeting siRNAs on SII-induced ERK1/2 activation in Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from four litters of neonatal rat pups; (b) depicts effect of barr1 targeting siRNAs on Ang II-induced ERK1/2 activation in Wistar rats brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from four litters of neonatal rat pups; (c) depicts effect of barr1 targeting siRNAs on Ang II-induced ERK1/2 activation in SHRs brainstem astrocytes. Each box represents the values of preparations of brainstem astrocytes isolated from four independent litters of neonatal rat pups. Black line within the boxes marks the median; symbol X within the boxes marks the mean; whiskers above and below the boxes indicate the maximum and minimum values of the data.
barr1 physiological functions in the SHR model has two down sides: first, the absence of the regulatory role of barr1 to dampen the deleterious effect of Ang II; as a result, we observed augmented Ang II-induced MAPKs activation. Alhough they are different cellular and receptor systems, the same effect has been demonstrated in adipocytes. Downregulation of barr1 resulted in super sensitization of b2-adrenergic receptors (b2AR) Gas signaling, which led to enhanced cAMP production (Hupfeld et al. 2003) . The second down side is the absence of the barr1-dependent MAPKs activation, which might have a beneficial effect in preventing the development of hypertension. It has been reported, in different cellular models, that almost 50% of the total MAPKs activation is attributed to barr1-dependent signaling, which is what we have observed in our Wistar rat astrocytes (Ahn et al. 2004; Oakley et al., 2009; Kim et al. 2009 ). In SHR brainstem astrocytes, the contribution of barr1 in this Ang II-mediated effect was diminished, suggesting a key role of this signaling pathway in these Ang II effects.
To delineate the Ang II-induced AT 1 R-mediated Gprotein-dependent and barr-dependent signaling, we employed the pharmacological inhibitor Suramin. In this study, treatment of astrocytes derived from brainstems of SHRs and Wistar rats with Suramin significantly inhibited Ang II-induced AT 1 R-mediated ERK1/2 activation, but did not abolish it. This result supports the notion that Ang IIinduced activation of ERK1/2 can occur by both G-proteindependent and -independent pathways (Morinelli et al. 2009 ). Furthermore, the inhibition of Ang II-induced ERK1/2 activation by Suramin appears to be greater in SHR astrocytes as compared to Wistar rat astrocytes. Presumably, this suggests that the Ang II-induced ERK1/2 activation in SHR astrocytes is predominantly G protein dependent. This inhibitory action of Suramin is selective to the G-protein-dependent pathway as the SII-induced ERK1/2 activation was not sensitive to Suramin treatment.
To further understand the role of G-protein and barr1-dependent signaling in Ang II-induced AT 1 R-mediated ERK1/2 activation, we applied gene silencing techniques to knockdown barr1. barr gene silencing technique is a widely used successful approach to study the roles of barr1 and/or 2 in different cellular systems such as VSMCs ) and primary astrocytes (McLennan et al. 2008) . Differential involvements of barr1 and 2 in GPCR ERK1/2 activations have been demonstrated. Depending on receptor and cell type, barr-dependent ERK1/2 activation can be blocked by depletion of both or either barr. For example, both barr1 and 2 are required for barrs-dependent ERK1/2 activation mediated by b2-adrenergic receptors (Drake et al. 2008) and parathyroid hormone receptors (Gesty-Palmer et al. 2006) . On the other hand, in VSMCs, only barr2 is required in AT 1 R-mediated ERK1/2 activation ). In our study, we observed complete abolishment of SII-induced AT 1 R-mediated ERK1/2 activations in barr1 Fig. 8 Effect of Suramin on Ang II-induced ERK1/2 activation in barr1 siRNA transfected SHRs and Wistar rats brainstem astrocytes. Posttransfected or non-transfected quiescent astrocytes were pre-treated with 100 lM Suramin for 30 min followed by treatment with 100 nM Ang II for 10 min. Other samples were treated with Ang II (100 nM) alone, or Suramin (100 lM) alone for 10 min, as described. Cell lysates were subjected to western blotting analysis and probed with a P-ERK1/2 antibody. The data are presented as fold of control that were obtained when P-ERK1/2 bands were normalized to beta-actin and further normalized to their controls. siRNA transfected astrocytes derived from the brainstems of Wistar rats. Similarly, reduced Ang II-stimulated AT 1 Rmediated ERK1/2 activation was observed in barr1 siRNA transfected astrocytes derived from the brainstems of Wistar rats and SHRs. Surprisingly, we observed higher inhibition of Ang II-induced AT 1 R-mediated ERK1/2 activation in barr1 astrocytes derived from the brainstems of Wistar rats as compared to astrocytes derived from the brainstems of SHRs. This could be an additional indication that in SHR astrocytes, Ang II-induced AT 1 R-mediated ERK1/2 activation is dominantly G protein dependent.
Various studies have demonstrated that ERK1/2 activation by AT 1 Rs and other GPCRs are mediated by both Gprotein-dependent and barr-dependent mechanisms Ahn et al. 2004; Ren et al. 2005; Gesty-Palmer et al. 2006; Darke et al., 2008; Lymperopoulos et al. 2009) . To assess the possible AT 1 R-mediated signaling pathways involved in ERK1/2 activation in SHR and Wistar rat astrocytes, we investigated the combined effect of the pharmacological reagent Suramin and siRNA-mediated barr1 gene silencing. Pre-treatment of barr1 siRNA posttransfected astrocytes with Suramin abolished Ang IIinduced AT 1 R-mediated ERK1/2 activation as compared to control siRNA transfected astrocytes. These results suggest that G-protein-and barr1-dependent pathways are the major pathways that mediate Ang II-induced AT 1 Rmediated ERK1/2 activation in astrocytes derived from the brainstems of SHRs and Wistar rats.
In summary, the barr1 isoform is the major endogenously expressed arrestin in both SHR and Wistar rat brainstem astrocytes, and its basal expression levels were significantly lower in SHR astrocytes as compared to Wistar rat astrocytes. Our findings are the first to demonstrate the involvement of barr1 in Ang II-induced AT 1 R-mediated MAPKs activation in brainstem astrocytes derived from SHRs and normotensive Wistar rats. This barr1-dependent MAPKs activation is reduced in astrocytes derived from brainstems of SHRs. The fact that we observed augmented Ang II-induced MAPKs activation in SHR brainstem astrocytes as compared to Wistar rat brainstem astrocytes, presumably, shows that the classical role of barr1, which is dampening of G protein-dependent MAPKs activation is lost in SHR brainstem astrocytes. Overall, our findings indicate that, rat brainstem astrocytic barr1 may have a crucial role in the regulation of blood pressure.
